AA
ALXO icon

AlphaCentric Advisors’s ALX Oncology ALXO Stock Holding History

AlphaCentric Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$527K Buy
+24,500
New +$1.06M 0.15% 61
2021
Q1 		– Sell
-1,500
Closed -$129K – 210
2020
Q4 		$129K Buy
1,500
+1,450
+2,900% +$87.2K 0.05% 97
2020
Q3 		$2K Buy
+50
New +$1.97K ﹤0.01% 164

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AlphaCentric Advisors's ALXO Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in ALX Oncology (ALXO) in Q4 2021: 24,500 shares worth $527K. The stake represents 0.15% of the portfolio and ranks #61 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in ALXO as recently as Q4 2020.

AlphaCentric Advisors first reported a position in ALXO in Q3 2020 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

  • AlphaCentric Advisors held 24,500 shares of ALX Oncology worth $527K as of Q4 2021.
  • ALX Oncology was a new AlphaCentric Advisors position in Q4 2021.
  • ALX Oncology made up 0.15% of AlphaCentric Advisors's portfolio in Q4 2021, its #61 holding.
  • AlphaCentric Advisors first reported a position in ALX Oncology in Q3 2020 and has held it in 3 quarters since.
  • 108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.